2022
Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study
Tamborlane WV, Laffel LM, Shehadeh N, Isganaitis E, Van Name M, Ratnayake J, Karlsson C, Norjavaara E. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. The Lancet Diabetes & Endocrinology 2022, 10: 341-350. PMID: 35378069, PMCID: PMC10851108, DOI: 10.1016/s2213-8587(22)00052-3.Peer-Reviewed Original ResearchConceptsType 2 diabetesPlacebo-assigned participantsPrespecified sensitivity analysisSafety of dapagliflozinPhase 3 studyBetween-group differencesAdverse eventsPrimary outcomeProtocol populationTreat analysisYoung adultsWeek double-blind periodRandomised phase 3 studyDouble-blind periodSerious adverse eventsNew safety signalsOral dapagliflozinDiabetic ketoacidosisSevere hypoglycaemiaMean ageTreatment optionsCare treatmentParallel groupSafety signalsStudy personnel
2021
Colonic Fermentation and Acetate Production in Youth with and without Obesity
Galuppo B, Cline G, Van Name M, Shabanova V, Wagner D, Kien CL, Santoro N. Colonic Fermentation and Acetate Production in Youth with and without Obesity. Journal Of Nutrition 2021, 151: 3292-3298. PMID: 34494088, PMCID: PMC8562084, DOI: 10.1093/jn/nxab277.Peer-Reviewed Original ResearchMeSH KeywordsAcetatesAdolescentColonFemaleFermentationGastrointestinal MicrobiomeHumansMaleObesityYoung AdultConceptsDe novo lipogenesisLean youthLactulose ingestionGut microbiotaHepatic de novo lipogenesisDevelopment of obesityColonic acetateOral doseIntravenous infusionPeripheral circulationColonic fermentationNovo lipogenesisObesityRate of appearanceAge 15Spearman correlationIngestionLactuloseRegression modelsMicrobiotaLesser degreeComplicationsGroupInfusionFerment carbohydrates
2020
Inequities in Diabetic Ketoacidosis Among Patients With Type 1 Diabetes and COVID-19: Data From 52 US Clinical Centers
Ebekozien O, Agarwal S, Noor N, Albanese-O’Neill A, Wong JC, Seeherunvong T, Sanchez J, DeSalvo D, Lyons SK, Majidi S, Wood JR, Acharya R, Aleppo G, Sumpter KM, Cymbaluk A, Shah NA, Van Name M, Cruz-Aviles L, Alonso GT, Gallagher MP, Sanda S, Feuer AJ, Cossen K, Rioles N, Jones NY, Kamboj MK, Hirsch IB. Inequities in Diabetic Ketoacidosis Among Patients With Type 1 Diabetes and COVID-19: Data From 52 US Clinical Centers. The Journal Of Clinical Endocrinology & Metabolism 2020, 106: 1755-1762. PMID: 33410917, PMCID: PMC7928931, DOI: 10.1210/clinem/dgaa920.Peer-Reviewed Original ResearchConceptsNH Black patientsLaboratory-confirmed COVID-19NH-White patientsDiabetic ketoacidosisType 1 diabetesNH blacksBlack patientsNH whitesWhite patientsHispanic patientsPotential confoundersLaboratory-confirmed coronavirus disease 2019COVID-19Multivariable logistic regression analysisUS clinical centersCross-sectional studyCOVID-19 infectionCoronavirus disease 2019Logistic regression analysisRace/ethnicity groupsMedian HbA1cSerious complicationsDKA eventsPatient factorsT1D patientsHealth Care Coverage and Glycemic Control in Young Adults With Youth-Onset Type 2 Diabetes: Results From the TODAY2 Study
Weinstock R, Braffett B, Songer T, Herman W, Kuo S, Gubitosi-Klug R, Laffel L, McKay S, Siska M, Van Name M, Zeitler P. Health Care Coverage and Glycemic Control in Young Adults With Youth-Onset Type 2 Diabetes: Results From the TODAY2 Study. Diabetes Care 2020, 43: 2469-2477. PMID: 32778555, PMCID: PMC7510035, DOI: 10.2337/dc20-0760.Peer-Reviewed Original ResearchConceptsType 2 diabetesHealth care coverageCare coverageGlycemic controlYoung adultsYouth-onset type 2 diabetesCommunity careYouth-Onset Type 2Medicaid expansionCommercial coverageCommunity diabetes careGovernment coverageDiabetes careDiabetes visitsTreatment optionsMore young adultsNew therapiesType 2DiabetesTODAY cohortCentral laboratoryVulnerable populationsCareCommercial plansHbAThe omentum of obese girls harbors small adipocytes and browning transcripts
Tarabra E, Nouws J, Vash-Margita A, Nadzam GS, Goldberg-Gell R, Van Name M, Pierpont B, Knight J, Shulman GI, Caprio S. The omentum of obese girls harbors small adipocytes and browning transcripts. JCI Insight 2020, 5 PMID: 32125283, PMCID: PMC7213797, DOI: 10.1172/jci.insight.135448.Peer-Reviewed Original ResearchConceptsSubcutaneous adipose tissueSAT depotsSleeve gastrectomySevere obesityInsulin resistanceInsulin sensitivitySmall adipocytesAdipose tissueAbdominal subcutaneous adipose tissueWeight lossType 2 diabetesOmental adipose tissueSubgroup of subjectsTranscriptomic profilesSAT biopsiesAdipocyte sizeObese girlsCardiovascular diseaseChildren and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control
Van Name MA, Cheng P, Gal RL, Kollman C, Lynch J, Nelson B, Tamborlane WV, Consortium F. Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control. Diabetic Medicine 2020, 37: 863-867. PMID: 31943374, DOI: 10.1111/dme.14233.Peer-Reviewed Original ResearchConceptsType 2 diabetesType 1 diabetesPediatric Diabetes ConsortiumTarget HbAType 1Median C-peptide levelsResidual endogenous insulin secretionType 2 diabetes mellitusC-peptide levelsEndogenous insulin secretionOverweight/obeseYears of agePoor diabetes outcomesSubset of participantsCharacteristics of childrenDiabetic ketoacidosisGlycaemic controlClinical characteristicsDiabetes mellitusDiabetes outcomesRisk factorsFamilies of childrenInsulin secretionInsulin treatmentDiabetes diagnosis
2017
Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes
Galderisi A, Sherr J, VanName M, Carria L, Zgorski M, Tichy E, Weyman K, Cengiz E, Weinzimer S, Tamborlane W. Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes. The Journal Of Clinical Endocrinology & Metabolism 2017, 103: 1088-1094. PMID: 29211871, PMCID: PMC6276715, DOI: 10.1210/jc.2017-02265.Peer-Reviewed Original ResearchConceptsMixed meal tolerance testPlasma glucagon responseWeeks of treatmentGlucagon responsePostprandial hyperglycemiaMeal-stimulated increaseWeeks of therapyPlasma glucagon levelsType 1 diabetesPlasma glucose curveBolus insulin administrationMixed meal feedingDl/minGlucagon curveAdjunctive treatmentGlucagon levelsPlasma glucagonTolerance testIncremental areaInsulin administrationGlucose curvePostmeal hyperglycemiaLiraglutideGlucose responsePretreatment responsesAltered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study
Patel NS, Van Name MA, Cengiz E, Carria LR, Weinzimer SA, Tamborlane WV, Sherr JL. Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study. Diabetes Technology & Therapeutics 2017, 19: 618-622. PMID: 29068709, PMCID: PMC5689123, DOI: 10.1089/dia.2017.0267.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsPlasma glucoseType 1 diabetesDiabetic ketoacidosisFree fatty acidsCANA treatmentBasal insulinGlucagon levelsMetabolic decompensationPlasma insulinInfusion site problemsCotransporter 2 inhibitorsBaseline plasma glucoseFailure of patientsBasal insulin infusionAdjunctive treatmentRate of ketogenesisSGLT2 inhibitorsT1D patientsT1D participantsInsulin infusionMagnitude of increasePG levelsSuspension studiesΒ-hydroxybutyrate
2016
Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study
Patel NS, Van Name MA, Cengiz E, Carria LR, Tichy EM, Weyman K, Weinzimer SA, Tamborlane WV, Sherr JL. Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study. Diabetes Technology & Therapeutics 2016, 18: 794-799. PMID: 27996320, PMCID: PMC5178000, DOI: 10.1089/dia.2016.0311.Peer-Reviewed Original ResearchConceptsClosed-loop insulin deliveryPlasma glucoseEnd of exercisePG levelsExercise studiesInsulin deliveryExercise periodCL insulin deliveryExercise-induced loweringType 1 diabetes subjectsExercise-induced reductionRecovery periodBrisk treadmillDL increaseRescue treatmentDiabetes subjectsInsulin infusionExerciseInsulinSimilar differencesVisitsCL controlDeliveryGlucosePeriodMitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide
Sherr JL, Patel NS, Michaud CI, Palau-Collazo MM, Van Name MA, Tamborlane WV, Cengiz E, Carria LR, Tichy EM, Weinzimer SA. Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide. Diabetes Care 2016, 39: 1127-1134. PMID: 27208332, PMCID: PMC4915555, DOI: 10.2337/dc16-0089.Peer-Reviewed Original ResearchConceptsAdjunctive agentsInsulin deliveryTotal daily insulin doseWeight lossDose escalation periodClosed-loop insulin deliveryDaily insulin dosePlasma glucose excursionsLoop insulin deliveryPrandial insulin deliveryContent of mealsConcomitant bluntingLiraglutide therapyDose titrationLiraglutide treatmentDose escalationInsulin doseGlycemic excursionsGlucose excursionsPostprandial hyperglycemiaPostprandial incrementLiraglutidePramlintideBeneficial effectsEscalation periodEffective Translation of an Intensive Lifestyle Intervention for Hispanic Women With Prediabetes in a Community Health Center Setting
Van Name MA, Camp AW, Magenheimer EA, Li F, Dziura JD, Montosa A, Patel A, Tamborlane WV. Effective Translation of an Intensive Lifestyle Intervention for Hispanic Women With Prediabetes in a Community Health Center Setting. Diabetes Care 2016, 39: 525-531. PMID: 26908915, PMCID: PMC4806769, DOI: 10.2337/dc15-1899.Peer-Reviewed Original ResearchMeSH KeywordsAdiposityAdolescentAdultAgedBody Mass IndexChoice BehaviorCommunity Health CentersDiabetes Mellitus, Type 2ExerciseFeasibility StudiesFemaleFood PreferencesHispanic or LatinoHumansInsulinLife StyleMiddle AgedPilot ProjectsPrediabetic StateRisk FactorsSocioeconomic FactorsWaist CircumferenceWeight LossYoung AdultConceptsIntensive lifestyle interventionDiabetes Prevention ProgramCommunity health center settingUsual care groupType 2 diabetesHealth center settingHispanic womenILI groupLifestyle interventionCare groupOral glucose tolerance testCenter settingLow-income Hispanic womenWeight lossSimilar baseline weightGlucose tolerance testPercent body fatType of interventionCHC settingsDPP interventionsUsual careBaseline weightWaist circumferenceGlucose excursionsTolerance test